Modulation of the Extent of Ischemic Brain Damage by Protecting the Endothelial Glycocalyx With Low-Dose Albumin Administration is a PHASE2 clinical asset sponsored by University Hospital Hradec Kralove in Ischemic Stroke. SEO and diligence focus: Albumin infusion, Placebo Injection, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.